Baker & McKenzie LLP

06/16/2025 | Press release | Distributed by Public on 06/16/2025 07:16

Baker McKenzie legal advisor to Xbrane in its primary issuance of shares of approximately SEK 240 million

Xbrane Biopharma AB has carried out an oversubscribed primary issuance of shares of approximately SEK 240 million through an accelerated bookbuilding procedure.

Xbrane develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm.

Pareto Securities acted as Sole Manager and Bookrunner. Baker McKenzie acted as legal advisor to Xbrane with a capital markets team consisting of Joakim Falkner, Johanna Flink, Carl Isaksson and Simon Olofsson.
Baker & McKenzie LLP published this content on June 16, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 16, 2025 at 13:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io